TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

TNF alfa blockers are widely used for treatment of severe psoriasis. These biologics are well-tolerated with few side effects.

Unfortunately not all patients respond adequately to treatment with tnf alfa blockers. Some do not respond at all while others respond initially but gradually lose effect despite increased dose and more frequent administration.

The cause of treatment failure is largely unknown and it may be production of tnf-alfa neutralizing antibodies. This has been demonstrated in patients with rheumatoid arthritis and inflammatory bowel disease who lost response after treatment with tnf-alfa blockers.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Collaborators: Pfizer; The Michaelsen Foundation
• Treatments: Adalimumab; Antibodies; Etanercept; Infliximab

Criteria

Inclusion Criteria:

• Male or female

• Age above 18

• Psoriasis

• Indication for treatment with tnf alfa blocking drug

• Written informed consent obtained

Exclusion Criteria:

• Severe psychiatric disorder

• No indication for treatment with tnf-alfa blocking drug

• Pregnancy

• Breastfeeding

• No written informed consent